Izotropic Corporation (IZO.CN)
CAD 0.04
(-20.0%)
CAD 0.04
(-20.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.56 Million CAD | 70.67% |
| 2022 | -5.34 Million CAD | 19.5% |
| 2021 | -6.63 Million CAD | -33.34% |
| 2020 | -4.97 Million CAD | -330.52% |
| 2019 | -1.15 Million CAD | -190.02% |
| 2018 | -398.53 Thousand CAD | 43.5% |
| 2017 | -705.4 Thousand CAD | -870.45% |
| 2016 | -72.68 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -270.02 Thousand CAD | 20.01% |
| 2023 Q3 | -245.14 Thousand CAD | 64.33% |
| 2023 FY | -1.69 Million CAD | 68.19% |
| 2023 Q1 | -417.95 CAD | 99.97% |
| 2023 Q2 | -687.18 Thousand CAD | -164315.94% |
| 2023 Q4 | -337.58 Thousand CAD | -37.71% |
| 2022 Q2 | -1.29 Million CAD | -34.15% |
| 2022 Q1 | -964.27 Thousand CAD | -63940.91% |
| 2022 FY | -5.34 Million CAD | 19.5% |
| 2022 Q4 | -1.21 Million CAD | 36.81% |
| 2022 Q3 | -1.91 Million CAD | -48.22% |
| 2021 Q2 | -2436.66 CAD | -108.38% |
| 2021 Q3 | -1199.13 CAD | 50.79% |
| 2021 Q4 | -1505.71 CAD | -25.57% |
| 2021 FY | -6.63 Million CAD | -33.34% |
| 2021 Q1 | -1169.34 CAD | 99.94% |
| 2020 Q2 | -371.31 Thousand CAD | 17.27% |
| 2020 FY | -4.97 Million CAD | -330.52% |
| 2020 Q4 | -1.9 Million CAD | 15.35% |
| 2020 Q3 | -2.25 Million CAD | -506.13% |
| 2020 Q1 | -448.81 Thousand CAD | 25.83% |
| 2019 Q2 | -155.38 Thousand CAD | -6.12% |
| 2019 FY | -1.15 Million CAD | -190.02% |
| 2019 Q4 | -605.14 Thousand CAD | -143.13% |
| 2019 Q1 | -146.42 Thousand CAD | -5.64% |
| 2019 Q3 | -248.89 Thousand CAD | -60.18% |
| 2018 Q2 | -94.39 Thousand CAD | -7.37% |
| 2018 Q3 | -77.62 Thousand CAD | 17.76% |
| 2018 Q4 | -138.6 Thousand CAD | -78.55% |
| 2018 FY | -398.53 Thousand CAD | 43.5% |
| 2018 Q1 | -87.91 Thousand CAD | 43.32% |
| 2017 Q3 | -68.98 Thousand CAD | 83.14% |
| 2017 Q4 | -155.11 Thousand CAD | -124.85% |
| 2017 FY | -705.4 Thousand CAD | -870.45% |
| 2017 Q1 | -72.07 Thousand CAD | -109.38% |
| 2017 Q2 | -409.22 Thousand CAD | -467.76% |
| 2016 Q2 | -22.1 Thousand CAD | -49.03% |
| 2016 Q1 | -14.83 Thousand CAD | 0.0% |
| 2016 Q4 | -34.42 Thousand CAD | -126.32% |
| 2016 FY | -72.68 Thousand CAD | 0.0% |
| 2016 Q3 | -15.21 Thousand CAD | 31.19% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioMark Diagnostics Inc. | -1.31 Million CAD | -19.05% |
| Sona Nanotech Inc. | -2.6 Million CAD | 39.918% |